title: Schistosomiasis and infection with human immunodeficiency virus 1 in rural Zimbabwe: systemic inflammation during co-infection and after treatment for schistosomiasis.
abstract: We previously reported that treatment for schistosomiasis in persons infected with human immunodeficiency virus 1 (HIV-1) attenuated HIV replication as measured by plasma HIV RNA. We investigated systemic inflammation as measured by plasma levels of soluble tumor necrosis factor-alpha receptor II (sTNF-rII), interleukin-8, (IL-8), and IL-10 during schistosomiasis and HIV co-infection and after schistosomiasis treatment. The cohort was composed of 378 persons who were or were not infected with HIV-1, Schistosoma haematobium, or S. mansoni. Schistosomiasis-infected persons were randomized to receive praziquantel (40 mg/kg) at baseline or at the three-month follow-up. sTNF-rII and IL-8 were positively associated with schistosomiasis intensity as measured by circulating anodic antigen (CAA), regardless of HIV status. Interleukin-10 was positively associated with CAA in HIV-negative participants. IL-8 levels were higher in S. mansoni-infected individuals. Treatment for schistosomiasis caused a decrease in levels of sTNF-rII (P < 0.05) and IL-10 (P < 0.001). Our results indicate that schistosomiasis treatment may attenuate HIV replication by decreasing systemic inflammation.
authors.affiliation: Department of Clinical Immunology, Aarhus University Hospital, Skejby Sygehus, Aarhus, Denmark. christian@erikstrup.org
authors.forename: Christian
authors.initials: C
authors.lastname: Erikstrup
authors.forename: Per
authors.initials: P
authors.lastname: Kallestrup
authors.forename: Rutendo B L
authors.initials: RB
authors.lastname: Zinyama-Gutsire
authors.forename: Exnevia
authors.initials: E
authors.lastname: Gomo
authors.forename: Govert J
authors.initials: GJ
authors.lastname: van Dam
authors.forename: André M
authors.initials: AM
authors.lastname: Deelder
authors.forename: Anthony E
authors.initials: AE
authors.lastname: Butterworth
authors.forename: Bente Klarlund
authors.initials: BK
authors.lastname: Pedersen
authors.forename: Sisse R
authors.initials: SR
authors.lastname: Ostrowski
authors.forename: Jan
authors.initials: J
authors.lastname: Gerstoft
authors.forename: Henrik
authors.initials: H
authors.lastname: Ullum
mesh_terms: D000293:Adolescent; D000328:Adult; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D016207:Cytokines / Q000097:blood; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000150:complications* / Q000453:epidemiology; D015497:HIV-1; D006801:Humans; D007249:Inflammation / Q000209:etiology*; D016753:Interleukin-10 / Q000097:blood; D016209:Interleukin-8 / Q000097:blood; D008297:Male; D008875:Middle Aged; D011223:Praziquantel / Q000627:therapeutic use; D047889:Receptors, Tumor Necrosis Factor, Type II / Q000097:blood; D012552:Schistosomiasis / Q000097:blood / Q000150:complications* / Q000188:drug therapy* / Q000453:epidemiology; D012556:Schistosomicides / Q000627:therapeutic use*; D015030:Zimbabwe / Q000453:epidemiology
chemical_list: D016207:Cytokines; D016209:Interleukin-8; D047889:Receptors, Tumor Necrosis Factor, Type II; D012556:Schistosomicides; D016753:Interleukin-10; D011223:Praziquantel